HCC Clinical Trial - Safety & Efficacy of Donafenib in Patients With

Status Completed

Clinical Trial Summary

This phase IB study of donafenib, an oral multikinase inhibitor that targets Raf kinase and receptor tyrosine kinases, is to assess toxicity,efficacy and pharmacokinetics in patients wiht advanced hepatocellular carcinoma (HCC) .

Clinical Trial Description

Eligibility Criteria:

- 18 -70 years old;

- Patients with measurable, histologically proven, inoperable HCC;

- Child-Pugh (CP) score of A;

- Eastern Cooperative Oncology Group (ECOG) performance status score of 2 or less.

- Patients received prior systemic treatments for HCC before 4 weeks;

- Patients received operate before 3 months;

- Patients received TACE before 4 weeks;

- Life expectancy at least 3 months;

- Adequate hepatic and renal function;

- Adequate hematologic function (platelet count,≥70×109per liter;hemoglobin ≥8.5 g per deciliter);

- Prothrombin time international normalized ratio≤2; or prothrombin time ≤16 seconds;or APTT≤43s;or TT≤21s.

Exclusion Criteria:

- Patients had prior treatment with sorafenib;

- CNS involvement.

Method:

- open-label,randomized,multiceters study;

- 2 dose cohorts: 200mg bid and 300mg bid;

- Patients with advanced HCC(inoperable) and Child-Pugh (CP) A , randomized,receive continuous donafenib either 200mg bid or 300mg bid in 4 weeks cycles;

- Sample size:106 patients(53 patients in each dose cohort).

Endpoints:

- Safety: toxicities are assessed according to CTCAE 3.0;

- TTP:Tumor response is assessed every two cycles using RECISIT1.1 criteria;

- Donafenib pharmacokinetics is measured in plasma samples. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02229071
Study type	Interventional
Source	Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Contact
Status	Completed
Phase	Phase 1/Phase 2
Start date	April 2014
Completion date	October 30, 2016

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT05458115` - Clinical Study of MRD Recurrence Monitoring After Surgical Resection of Hepatocellular Carcinoma
Not yet recruiting	`NCT05022628` - Clinical Study of Radiotherapy Combined With Donafenib for Neoadjuvant Treatment of Patients With HCC With Portal Vein Carcinoma Thrombosis	Phase 4
Enrolling by invitation	`NCT02256514` - Open Label Trial of Immunotherapy for Advanced Liver Cancer	Phase 2
Not yet recruiting	`NCT06434480` - SBRT in HCC With Oligoprogression on Atezo-Bev	N/A
Completed	`NCT04542837` - The Study of KN046 in Combination With Lenvatinib in Advanced Hepatocellular Carcinoma	Phase 2
Not yet recruiting	`NCT05025592` - cTACE or DEB-TACE+HAIC Combined With Regorafenib ± Anti-PD1 Antibody for uHCC
Completed	`NCT04172506` - A Study to Evaluate the Efficacy and Safety of Anti-PD-1 Antibody AK105 in Patients With Selected Advanced Solid Tumors	Phase 1/Phase 2
Not yet recruiting	`NCT06024252` - Efficacy, Safety, and Treatment Patterns of Transcatheter Arterial Chemoembolization (TACE) Combined With Atezolizumab and Bevacizumab in Unresectable Hepatocellular Carcinoma: a Multicenter, Retrospective, Observational Real-world Study
Not yet recruiting	`NCT05840133` - Study of Long Non-coding RNA SNHG15 as a Novel Biomarker in HBV Associated HCC
Terminated	`NCT02785874` - Statin With Palliative Therapy for HCC	N/A
Not yet recruiting	`NCT02715492` - Role of (LMWH) in Prevention of Thromboembolic Complication After (TACE) in Hepatocellular Carcinoma.	Phase 3
Completed	`NCT02985034` - Safety Margin Assessment After RFA Using the Registration of Pre-ablation MRI and Post-ablation CT	N/A
Not yet recruiting	`NCT06069947` - SALT for Liver Cirrhosis With HCC	N/A
Recruiting	`NCT05581004` - A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors	Phase 1
Suspended	`NCT02935478` - Bariatric Embolization of Arteries in Obese Patients With HCC to Allow Salvage Liver Transplantation	N/A
Recruiting	`NCT05592171` - Occlusafe® Assisted MW Alone or With DEB-TACE Compared to MW With DEB-TACE in the Treatment of HCC	N/A
Completed	`NCT03176485` - Evaluation of Pathway Modulation by Raf, MEK, & Kinase Inhibitors	N/A
Recruiting	`NCT05544253` - Safety and Efficacy of Mitomycin C-based HIPEC After srHCC and PM of HCC	Phase 2/Phase 3
Recruiting	`NCT06184152` - CEUS vs. AMRI for HCC Detection in Patients With Indeterminate Liver Nodules
Completed	`NCT02675920` - A Study of HCC High Risk Group Using Two Surveillance Tools

Safety and Efficacy of Donafenib in Patients With Advanced Hepatocellular Carcinoma

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms